Recruiting — multicenter field trial
What is being offered: Official sponsor recruitment notice dated 2025-10-26 remains publicly listed; sponsor subsequently announced regulatory approval to conduct the Taiwan field trial on 2025-11-03 and continues to describe PT001 as an active oncology development program in 2026. Multicenter randomized open-label two-arm field trial of PT001, a PD-L1 and CTLA-4 recombinant-protein therapeutic vaccine, for confirmed stage II-III canine oral malignant melanoma. Age >=1 year. Owners must agree to suspend other cancer treatment. Excludes severe liver/kidney disease, autoimmune disease, bone-marrow disease or other high-risk systemic disease, dogs requiring steroids/immunosuppressants, and prior radiation. Tumor must be recordable/measurable. Trial contains a control arm. Final screening by study site is required.
Who may qualify: Confirmed cancer diagnosis required; Min age years: 1; Measurable; Oral melanoma stage ii or iii; Other treatments suspended
May not qualify if: Prior local radiation; Current steroids; Immunosuppressive
Costs / coverage: The current protocol page does not state which treatment, testing or follow-up costs are covered; confirm directly with the study team.
Contact: Participating veterinary hospitals listed on the official recruitment page; screening through the study sites.
Location
- Duma Animal Hospital, No. 136 Zhongyuan St, Zhonghe Dist, New Taipei City, Taiwan